Balchem Corporation (BCPC) Q4 2025 Financial Results Summary
· Stocks · QuoteReporter
Balchem Corporation (BCPC) Q4 2025 Financial Results Summary
Montvale, NJ, February 20, 2026 – Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2025 fiscal fourth quarter and full year ended December 31, 2025.
Fourth Quarter 2025 Financial Highlights
- Net Sales: $263.6 million, an increase of 9.8% compared to $240.0 million in Q4 2024.
- Net Earnings: $39.2 million, up 16.8% from $33.6 million in Q4 2024.
- Adjusted EBITDA: $67.9 million, reflecting an increase of 8.1% from $62.8 million in the same quarter last year.
- GAAP Earnings Per Share (EPS): $1.21 compared to $1.03 in Q4 2024.
- Adjusted EPS: $1.31, up from $1.13 in the prior year.
- Cash Flows from Operations: $67.3 million; Free Cash Flow: $51.2 million, a notable increase from $39.8 million in Q4 2024.
Full Year 2025 Financial Highlights
- Net Sales: $1.037 billion, a record high and an increase of 8.8% compared to $953.7 million in 2024.
- Net Earnings: $154.8 million, an increase of 20.5% from $128.5 million in the prior year.
- GAAP EPS: $4.75, compared to $3.93 in 2024.
- Adjusted EBITDA: $274.9 million, an increase of 9.8% from $250.3 million in 2024.
- Adjusted Net Earnings: $167.9 million, up 17.4% from $143.0 million in 2024.
- Free Cash Flow: $173.6 million, a significant increase from $147.2 million in the previous year.
Segment Performance
- Human Nutrition & Health:
- Sales: $166.1 million, up 12.7% from $147.3 million in Q4 2024.
- Earnings from Operations: $36.8 million, an increase of 8.9% from $33.8 million last year.
- Animal Nutrition & Health:
- Sales: $61.2 million, increased by 4.9% from $58.3 million in the prior year.
- Earnings from Operations: $6.2 million, up 8.6% from $5.7 million in Q4 2024.
- Specialty Products:
- Sales: $34.8 million, a rise of 6.0% from $32.9 million in Q4 2024.
- Earnings from Operations: $10.5 million, an increase of 5.5% from $10.0 million last year.
Balance Sheet & Cash Flow
- Gross Margin: $93.9 million for the quarter, an increase of 8.8% from $86.3 million in Q4 2024. The gross margin as a percentage of sales decreased by 40 basis points to 35.6%.
- Operating Expenses: $41.6 million for the quarter, up 6.9% from $38.9 million in Q4 2024.
- Cash balance of $74.6 million as of December 31, 2025, compared to $49.5 million in 2024.
- Significant cash payments included:
- Repurchase of common stock: $53.6 million
- Dividends paid: Increased amount of $28.3 million compared to $25.6 million paid in Q4 2024.
Dividend & Share Repurchase
- Dividend Increase: The company announced a double-digit percentage increase in its quarterly dividend, continuing its commitment to shareholder returns.
- Share Repurchase Program: The company repurchased common stock amounting to $53.6 million during the quarter.
Conclusion
Balchem delivered strong financial results for both the fourth quarter and full year of 2025, with robust growth across all business segments. The company’s focus on sustainability and its capacity to align with market trends appear to have contributed to its success. As Balchem prepares for the future, it is well-positioned for continued growth and value creation for its shareholders.
Note: All amounts in the following tables are in thousands.
| Three Months Ended | Year Ended | |||
|---|---|---|---|---|
| December 31, 2025 | December 31, 2024 | December 31, 2025 | December 31, 2024 | |
| Net sales | $263,617 | $240,004 | $1,037,161 | $953,684 |
| Gross margin | $93,899 | $86,337 | $370,633 | $336,206 |
| Operating expenses | $41,609 | $38,893 | $161,307 | $153,297 |
| Earnings from operations | $52,290 | $47,444 | $209,326 | $182,909 |
| Interest and other expenses | $2,255 | $2,960 | $10,296 | $16,456 |
| Earnings before income tax expense | $50,035 | $44,484 | $199,030 | $166,453 |
| Income tax expense | $10,810 | $10,901 | $44,185 | $37,978 |
| Net earnings | $39,225 | $33,583 | $154,845 | $128,475 |
| Diluted net earnings per common share | $1.21 | $1.03 | $4.75 | $3.93 |
| Adjusted EBITDA(a) | $67,893 | $62,833 | $274,854 | $250,348 |
| Adjusted net earnings(a) | $42,338 | $36,876 | $167,898 | $142,965 |
| Adjusted diluted net earnings per common share(a) | $1.31 | $1.13 | $5.15 | $4.37 |
| Shares used in the calculations of diluted and adjusted net earnings per common share | 32,320 | 32,548 | 32,604 | 32,718 |
(a) See “Non-GAAP Financial Information” for a reconciliation of GAAP and non-GAAP financial measures.
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Cash and cash equivalents | $74,570 | $49,515 |
| Accounts receivable, net | $143,596 | $119,662 |
| Inventories | $131,449 | $130,802 |
| Other current assets | $15,999 | $13,791 |
| Total current assets | $365,614 | $313,770 |
| Property, plant and equipment, net | $306,648 | $282,154 |
| Goodwill | $816,375 | $780,030 |
| Intangible assets with finite lives, net | $163,289 | $165,050 |
| Right of use assets | $16,192 | $17,050 |
| Other assets | $18,134 | $17,317 |
| Total non-current assets | $1,320,638 | $1,261,601 |
| Total assets | $1,686,252 | $1,575,371 |
| Current liabilities | $176,384 | $157,685 |
| Revolving loan | $164,000 | $190,000 |
| Deferred income taxes | $54,143 | $43,722 |
| Other long-term obligations | $34,312 | $34,051 |
| Total liabilities | $428,839 | $425,458 |
| Stockholders’ equity | $1,257,413 | $1,149,913 |
| Total liabilities and stockholders’ equity | $1,686,252 | $1,575,371 |